These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34486106)

  • 1. MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy.
    Bohosova J; Vajcner J; Jabandziev P; Oslejskova H; Slaby O; Aulicka S
    Epilepsia; 2021 Nov; 62(11):2573-2588. PubMed ID: 34486106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing a gene panel for pharmacoresistant epilepsy: a review of epilepsy pharmacogenetics.
    Rodriguez-Acevedo AJ; Gordon LG; Waddell N; Hollway G; Vadlamudi L
    Pharmacogenomics; 2021 Mar; 22(4):225-234. PubMed ID: 33666520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA therapeutics for epilepsy: An emerging modality for drug discovery.
    Hansen SN; Holm A; Kauppinen S; Klitgaard H
    Epilepsia; 2023 Dec; 64(12):3113-3129. PubMed ID: 37703096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments.
    Xu C; Gong Y; Wang Y; Chen Z
    Pharmacol Ther; 2022 May; 233():108026. PubMed ID: 34718071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.
    Löscher W
    Neurochem Res; 2017 Jul; 42(7):1873-1888. PubMed ID: 28290134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuing Burden of Refractory Epilepsy.
    Janson MT; Bainbridge JL
    Ann Pharmacother; 2021 Mar; 55(3):406-408. PubMed ID: 32795085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy.
    Wilcox KS; West PJ; Metcalf CS
    Neuropharmacology; 2020 Apr; 166():107811. PubMed ID: 31790717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy.
    Campos G; Fortuna A; Falcão A; Alves G
    Epilepsy Res; 2018 Oct; 146():63-86. PubMed ID: 30086482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamotrigine-resistant corneal-kindled mice: A model of pharmacoresistant partial epilepsy for moderate-throughput drug discovery.
    Koneval Z; Knox KM; White HS; Barker-Haliski M
    Epilepsia; 2018 Jun; 59(6):1245-1256. PubMed ID: 29750337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the action mechanisms and targets of herbal anticonvulsants highlights opportunities for therapeutic engagement with refractory epilepsy.
    Tabassum S; Shorter S; Ovsepian SV
    J Mol Med (Berl); 2024 Jun; 102(6):761-771. PubMed ID: 38653825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of plasma microRNA-145-5p and its correlation with clinical features in patients with refractory epilepsy.
    Shen CH; Zhang YX; Zheng Y; Yang F; Hu Y; Xu S; Yan SQ; Ding Y; Guo Y; Ding MP
    Epilepsy Res; 2019 Aug; 154():21-25. PubMed ID: 31022636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.
    Barker-Haliski ML; Johnson K; Billingsley P; Huff J; Handy LJ; Khaleel R; Lu Z; Mau MJ; Pruess TH; Rueda C; Saunders G; Underwood TK; Vanegas F; Smith MD; West PJ; Wilcox KS
    Neurochem Res; 2017 Jul; 42(7):1904-1918. PubMed ID: 28303498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique behavioral characteristics and microRNA signatures in a drug resistant epilepsy model.
    Moon J; Lee ST; Choi J; Jung KH; Yang H; Khalid A; Kim JM; Park KI; Shin JW; Ban JJ; Yi GS; Lee SK; Jeon D; Chu K
    PLoS One; 2014; 9(1):e85617. PubMed ID: 24454901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
    Vanhoof-Villalba SL; Gautier NM; Mishra V; Glasscock E
    Epilepsia; 2018 Feb; 59(2):358-368. PubMed ID: 29265344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A resurging boom in new drugs for epilepsy and brain disorders.
    Younus I; Reddy DS
    Expert Rev Clin Pharmacol; 2018 Jan; 11(1):27-45. PubMed ID: 28956955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Models in research of pharmacoresistant epilepsy: present and future in development of antiepileptic drugs.
    Kovács R; Heinemann U
    Curr Med Chem; 2014; 21(6):689-703. PubMed ID: 24251565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.
    Löscher W; Potschka H; Sisodiya SM; Vezzani A
    Pharmacol Rev; 2020 Jul; 72(3):606-638. PubMed ID: 32540959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for early identification of pharmacoresistant epilepsy.
    Sporis D; Basić S; Susak I; Colak Z; Marković I
    Acta Clin Croat; 2013 Mar; 52(1):11-5. PubMed ID: 23837267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating microRNA: The Potential Novel Diagnostic Biomarkers to Predict Drug Resistance in Temporal Lobe Epilepsy, a Pilot Study.
    De Benedittis S; Fortunato F; Cava C; Gallivanone F; Iaccino E; Caligiuri ME; Castiglioni I; Bertoli G; Manna I; Labate A; Gambardella A
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research Progress on the Role of ABC Transporters in the Drug Resistance Mechanism of Intractable Epilepsy.
    Xiong J; Mao DA; Liu LQ
    Biomed Res Int; 2015; 2015():194541. PubMed ID: 26491660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.